Our goal is to develop broad spectrum, small molecule antivirals with high barriers to resistance against multiple Priority Pathogens. We discovered a novel specific phosphoinositide (PI)-4,5-bisphosphate (PI(4,5)P2, or
In summary, we seek to develop new classes of host-targeting antiviral therapeutics based on inhibition of Pl-4- and PIP5- kinases, and that are capable of treating multiple NIAID Emerging and Re-emerging Priority Pathogen viruses, when used alone or in combination with other available agents.
|Cho, Nam-Joon; Lee, Choongho; Pang, Phillip S et al. (2015) Phosphatidylinositol 4,5-bisphosphate is an HCV NS5A ligand and mediates replication of the viral genome. Gastroenterology 148:616-25|